Reduced Type‐I Interferon by Plasmacytoid Dendritic Cells and Asthma in School‐Aged Children
Allergy, Volume 81, Issue 1, Page 109-120, January 2026.Low type‐I interferon response to in vitro stimulation of plasmacytoid dendritic cells (pDC) with a TLR7/8 agonist (R848) is associated with current asthma in school‐aged children. Low type‐I interferon response is associated with increased level of atopy but appears to have limited impact on early life viral infection susceptibility.
Isabelle Coenen +14 more
wiley +1 more source
Long-Term Outcomes of Omalizumab in Chronic Idiopathic Urticaria (CIU): Evidence from a Large Allergy Practice in the United States (US) [PDF]
, 2019 Jason Lecocq +7 more
openalex +1 more source
Allergy, Volume 81, Issue 1, Page 130-144, January 2026.In the LEAD cohort, micro‐arrayed asthma allergens identified IgE‐sensitized adult asthma patients. Compared to non‐IgE‐sensitized patients, they had better lung function, took less ICS and had lower eosinophils. IgE‐sensitized patients were sensitized to a handful of respiratory allergen sources and may benefit from allergen‐specific forms of ...
Huey‐Jy Huang +20 more
wiley +1 more source
Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘real-world’ evidence [PDF]
, 2018 Jonathan A. Bernstein +6 more
openalex +1 more source
Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta‐Analysis
Allergy, Volume 81, Issue 1, Page 24-55, January 2026.ABSTRACT Biologics are effective for severe asthma, but not all patients benefit equally. There is an urgent need to understand which biologic works best for which patient. We systematically searched for predictors of response to biologics (except omalizumab) for severe asthma in four bibliographic databases and two trial registries from 1990 to 2024 ...
Anna Rattu +22 more
wiley +1 more source
The role of omalizumab in the treatment of adults with severe allergic asthma
Zdravniški Vestnik, 2013 Backg round: Omalizumab is a recombinant humanized anti-IgE antibody. It has been used in the treatment of severe allergic asthma since 2007 in Slovenija.
Sabina Škrgat Kristan
doaj
Omalizumab significantly reduces asthma exacerbations in patients with severe persistent asthma: A pooled analysis [PDF]
, 2005 William Berger +5 more
openalex +1 more source
Expanding the Immunologic and Neuronal Landscape of IgE‐Mediated Anaphylaxis
Immunological Reviews, Volume 337, Issue 1, January 2026.ABSTRACT Anaphylaxis is a life‐threatening immunoglobulin E (IgE)‐mediated type I hypersensitivity reaction with rising prevalence and burden. It involves mast cell degranulation upon cross‐linking of antigen on mast cell‐bound IgE. Mechanisms of IgE‐mediated anaphylaxis remain incompletely understood, particularly the induction of systemic symptoms ...
Ruchi Biswas +2 more
wiley +1 more source